MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.975
-0.075
-3.66%
Opening 12:07 01/02 EST
OPEN
2.070
PREV CLOSE
2.050
HIGH
2.089
LOW
1.970
VOLUME
108.62K
TURNOVER
--
52 WEEK HIGH
3.490
52 WEEK LOW
1.330
MARKET CAP
238.78M
P/E (TTM)
-1.7202
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IKT last week (1222-1226)?
Weekly Report · 12/29/2025 09:11
Dynavax, Inhibikase and More: Stocks Trending by Analysts
TipRanks · 12/27/2025 09:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/26/2025 17:05
Inhibikase Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 12/26/2025 11:19
Inhibikase Therapeutics Price Target Announced at $8.00/Share by HC Wainwright & Co.
Dow Jones · 12/26/2025 11:19
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
TipRanks · 12/26/2025 11:15
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8
Benzinga · 12/26/2025 11:10
INHIBIKASE THERAPEUTICS INC <IKT.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $8
Reuters · 12/26/2025 11:09
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.